Judge Dismisses Teva API Patent Challenge Against Mylan, Sandoz

A district court judge granted motions to dismiss filed by Mylan and Sandoz after the companies agreed to abstain from using a method of measuring the active pharmaceutical ingredient (API) for multiple sclerosis drug Copaxone that Teva had challenged infringed on four of its patents.
Washington Drug Letter